Market cap
$539.6m
End-of-day close multiplied by current shares on issue.
Underlying EBITDA held near NZ$37.6m, but receivables expanded NZ$110.5m and debtor days hit 168.5 against a historical mean of 22.7 days.
Revenue context before the current result.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Statutory profit after tax across covered periods.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$539.6m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
10.3x
Recent market cap compared with trailing earnings.
EPS
0.07
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
12.92x
Enterprise value compared with recent EBITDA.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
0.47x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY24 vs HY23
Revenue
$131.6m
-24.0% ↓ vs $173.3m
EBITDA
$37.6m
— vs —
Net profit after tax
$35.2m
+246.1% ↑ vs −$24.1m
Net cash inflow from operating activities
$48m
+102.5% ↑ vs $23.7m
Declared dividend per share
0.0c
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Profit before tax
$32.4m
+199.7% ↑ vs −$32.5m
Cash and cash equivalents
$10.3m
-43.6% ↓ vs $18.3m
Total assets
$2.7b
+8.7% ↑ vs $2.5b
What changed
Against that balance-sheet backdrop, profit before tax swung from a NZ$32.5m loss to a NZ$32.4m profit (+199.5%), and net profit after tax recovered to NZ$35.2m (+245.7%).
Headline revenue fell 24.0% to NZ$131.6m, but management reports operating revenue up roughly 8% versus a comparable NZ$122.1m base — the statutory decline reflects lower development and resale gains included in HY23's revenue line. Underlying EBITDA was NZ$37.6m, broadly in line with HY23's NZ$38.7m. Operating cash flow doubled to NZ$48.0m, capex collapsed 79.0% to NZ$23.8m, and pre-lease free cash flow swung to NZ$24.2m. The interim dividend was cut to nil from 1.25 cents.
What matters
Trade debtors at NZ$121.5m and debtor days of 168.5 sit far outside the company's historical range. Without disclosure on composition, the most likely explanation is settled-but-uncollected village resales sitting in receivables, which means the reported NZ$48.0m operating cash inflow likely draws on legacy ORA receipts rather than current period revenue conversion.
The statutory revenue decline is misleading. Operating revenue actually grew 8% to NZ$131.6m on management's comparable basis; the 24.0% headline drop reflects lower realised gains on development and resales included in HY23's revenue. Total sales volumes were up 13% and new sale volumes up 38%, which supports an underlying volume story rather than a demand collapse.
Leverage worsened and the dividend was withdrawn. Gross borrowings rose to NZ$621.4m, net debt to NZ$611.1m, and cash fell to NZ$10.3m. The board cut the interim dividend to nil and rebased its policy to 30–50% of underlying NPAT (from underlying EBIT). Balance-sheet flexibility, not operating profit, is now the binding constraint.
Expectations
The supplied seasonality pattern is heavily second-half-weighted: HY23 represented 70.1% of FY23 revenue but -156.2% of FY23 NPAT, meaning the prior H1 loss was more than offset by H2 settlement gains. On that pattern, HY24's NZ$32.4m PBT already exceeds FY23's full-year NPAT of NZ$15.4m.
The more important second-half question is whether the NZ$121.5m receivable balance converts to cash. That, rather than reported earnings, will set FY24 net debt and the path to dividend resumption under the new policy.
Quality of result
Underlying EBITDA of NZ$37.6m essentially matched the prior period, so the swing to a NZ$32.4m PBT is driven by lower non-cash fair-value movements on investment property rather than operating expansion. The effective tax rate of -8.6% added a tax credit, so PBT growth of 199.5% is the cleaner read on operating performance than NPAT growth of 245.7%.
Cash quality is where the result is weakest. Pre-lease free cash flow of NZ$24.2m is driven almost entirely by capex collapsing from NZ$113.3m to NZ$23.8m as Oceania completes its development pipeline, not by operating cash generation. Reported operating cash conversion of 127.6% of underlying EBITDA looks healthy in isolation, but trade debtors rose NZ$110.5m over the same window — meaning collections against current revenue were materially below 100% before favourable ORA cash receipts closed the gap. ROE of 3.5% is barely meaningful given the swing nature of the result.
Unresolved
This briefing cannot assess the composition of the trade debtor balance or the timing of expected settlement collections without supplementary disclosure.
Chat
Ask follow-up questions about Oceania Healthcare's HY24 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
Interim Report
HY24 / financial reportInvestor Presentation
HY24 / results presentationMedia Release
HY24 / media releaseResults Announcement
HY24 / results announcementNotice of Half Year Result Announcement
HY23 / financial reportMedia Release
FY23 / financial reportResults Announcement
FY23 / results announcementRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 46.2pp, with a distortion flag in the result.
Leverage and balance-sheet risk
Net debt / EBITDA is 16.20x, +9.40x versus the prior comparable period.
Revenue growth context
Revenue growth was -24.0% for this reporting period.
Cash conversion quality
This result converted 127.6% of EBITDA to operating cash flow.
Get the next Oceania Healthcare briefing and related NZX reporting-season updates by email.